Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR 5.02
+0.47 (10.33%)
May 11, 2026, 5:35 PM CET
Inventiva Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
It also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Inventiva S.A.
| Country | France |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 77 |
| CEO | Andrew Obenshain |
Contact Details
Address: 50 rue de Dijon Daix, 21121 France | |
| Phone | 33 3 80 44 75 00 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | IVA |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013233012 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Obenshain | Chief Executive Officer |
| Dr. Pierre Broqua Ph.D. | Co-Founder |
| Jean Volatier | Executive Vice President Finance and Corporate Social Responsibility |
| Dr. Martine Zimmermann Pharm.D. | Executive Vice President of Regulatory Affairs and Quality Assurance and Head of Regulatory Affairs |
| Jason A. Campagna M.D., Ph.D. | President of Research and Development and Chief Medical Officer |
| Axel-Sven Malkomes | Chief Financial Officer |
| Susan Coles | Chief Legal Officer |
| Pamela Herbster | Chief People Officer |
| Eric Duranson L.L.M. | General Counsel |
| Pascaline Clerc Ph.D. | Executive Vice President of External and Corporate Affairs |